Bantam Pharmaceutical, LLC

Boehringer Ingelheim International Gmbh

Genentech, Inc.

Medivir Ab

Chantal Grand-Maitre

Lea Constantineau-Forget

Alan B Cooper

Stephane Ciblat

Gerald W Shipps

Cyrille Kuhn

Martin Dery

M Arshad Siddiqui

Christian Brochu

Nicolas Bruneau-Latour

Xiangyu Guo

Sanjay Srivastava

Elisia Villemure

Vu Linh Ly

Marc Pesant

Michael Luther

Jedd Levine

Megan Bertrand-Laperle

Vibha Oza

Huifen Chen

Brian Salvatore Safina

Pierre Louis Beaulieu

Jean Rancourt

Matthew J Kostura

Matthew Volgraf

Benoît Moreau

Stuart Ward

Lee Fader

Daniel Shore

Carl Thibeault

Aijun Lu

Robin Larouche-Gauthier

Melissa Leblanc

Francis Beaumier

Simon Surprenant

Luce Lépissier

Eric Jolicoeur

Oliver Hucke

Jack Alexander Terrett

Jean-Eric Lacoste

Marc-Andre Joly

Araz Jakalian

Patrick Deroy

Louis Morency

Martin Tremblay

Anne Décor

Arshad M Siddiqui

Matthew W Kostura

Claudio Sturino

Teddy Halmos

Anne Decor

Martin Duplessis

Anne DÉCOR

Pierre L Beaulieu

Disclosed are methods of treating hyperproliferative disorders such as cancer, methods of arresting the cell cycle in cancer cells, methods of inhibiting glutathione synthesis in cancer cells, and associated compounds for use and uses in medicaments. In certain embodiments, the methods, uses and compounds are provided with reference to compounds of the structural formula (I), in which X, X, Z, Z, the ring system denoted by 'a', R, L, L, Q, L, R, L, R, L, and Rare as described herein. In certain embodiments, compounds disclosed herein are especially active against cancers having a mutant KRAS gene.

Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases

Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts and N-oxides thereof, wherein X, X, Z, Z, the ring system denoted by 'a', R, A, L, A, L, L, Q, L, R, A, L, A, L, R, L, and Rare as described herein. In certain embodiments, compounds disclosed herein disrupt the eIF4E/eiF4G interaction, and can be used to treat hyperproliferative disorder, a neurological disease or disorder, or autism.

Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto

Disclosed are compounds useful, for example, in methods of treating hyperproliferative disorders such as cancer, methods of arresting the cell cycle in cancer cells, methods of inhibiting glutathione synthesis in cancer cells, and associated compounds for use and uses in medicaments. In certain embodiments, the methods, uses and compounds are provided with reference to compounds of the structural formulae (Ia), (Ib), (Ic), (Id) and (Ie), in which R, L, L, Q, L, R, L, R, L, and Rare as described herein. In certain embodiments, compounds disclosed herein are especially active against cancers having a mutant KRAS gene. 

Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases

The invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Oxadiazole transient receptor potential channel inhibitors

Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure (I) and pharmaceutically acceptable salts and/V-oxides thereof, wherein X, X, Z, Z, the ring system denoted by 'a', R, A, L, A, L, L, Q, L, R, A, L, A, L, R, L, and Rare as described herein. In certain embodiments, compounds disclosed herein disrupt the eIF4E/eiF4G interaction, and can be used to treat hyperproliferative disorder, a neurological disease or disorder, or autism. 

Compounds of Formula (I), wherein R, R, R, Rand n are defined herein, are useful as inhibitors of RSV. 

Respiratory syncytial virus inhibitors

Compounds of Formula (I) wherein R, R, R, R, Y, Zand Zare defined herein, are useful for the treatment of cytomegalovirus disease and/or infection. 

Inhibitors of cytomegalovirus

A compound of formula (I) useful for the treatment or prevention of hepatitis C viral infection, (Formula (I)) wherein: Xand Xare each independently CRor N; Ris H, (C)alkyl, (C)haloalkyl, halo. &#x2014;O&#x2014;(C)alkyl, NH, NH(C)alkyl or N((C)alkyl); Rand Rare each independently (C)alkyl optionally mono- or di-substituted with &#x2014;O&#x2014;(C)alkyl, NH, NH(C)alkyl or N((C)alkyl); or Rand R, together with the carbon to which they are attached, are linked to form a (C)cycloalkyl group or a 3- to 7-membered heterocyclyl, said cycloalkyl and heterocyclyl being optionally mono- or di-substituted with &#x2014;(C)alkyl; Ris &#x2014;C(&#x2550;O)N(R)(R), &#x2014;C(&#x2550;O)O(R), heterocyclyl or heteroaryl, wherein each said heterocyclyl and heteroaryl is optionally substituted 1 to 3 times with R; Rand Rare each independently H or (C)alkyl optionally mono- or di-substituted with &#x2014;O&#x2014;(C)alkyl, NH, NH(C)alkyl or N((C)alkyl); or Rand R, together with the carbon to which they are attached, are linked to form a (C)cycloalkyl group or a 3- to 7-membered heterocyclyl, said cycloalkyl and heterocyclyl being optionally mono- or di-substituted with &#x2014;(C)alkyl; and n is 0, 1 or 2. 

Hepatitis C inhibitor compounds

The invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein R, R, Rand Rare defined herein, and their use for the treatment of hepatitis C viral infection.

Substituted pyrazolo[3,4-a]carbazoles as hepatitis C inhibitors

Growing community of inventors

Boisbriand, Canada

Chantal Grand-Maitre